Table 3.

Pulmonary arterial hypertension characteristics and clinical data

Pulmonary arterial hypertension etiology
Idiopathic	25 (63%)
Hereditary	4 (10%)
Associated with diet drug use	2 (5%)
Portopulmonary Hypertension	1 (2%)
Associated with Connective Tissue Disease	8 (20%)
WHO Class
I/II	27 (67.5%)
III/IV	13 (32.5%)
Six-minute walk distance (m) [% pred.]	453 ± 105 [80 ± 19]
Log N-terminal pro-B-type nautriuretic peptide (pg/mL)	752 ± 1229 [2.28 ± 0.68]
Echocardiography Data
Right Ventricle Systolic Pressure (mmHg)	76 ± 23
Tricuspid Annular Plane Systolic Excursion by M-mode (mm)	21 ± 5
Lateral Annulus Systolic Velocity (msec)	0.13 ± 0.03
Pulmonary Function Data	(n = 32)
Forced Ventilatory Capacity (L) [% pred.]	3.2 ± 0.8 [86 ± 16]
Forced Expiratory Volume in 1 second (L) [% pred.]	2.5 ± 0.6 [80 ± 14]
Diffusion Capacity for Carbon Monoxide (ml/min/mmHg) [% pred.]	17.6 ± 4.8 [71 ± 14]
Medications
Endothelin Antagonist	58%
Phosphodiesterase type-5 Inhibitor	73%
Prostacyclin	48%
Digitalis	33%
Diuretic	60%

Data presented as mean ± standard deviation, and frequency (%).